Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Rabbit Monoclonal Antibodies Now Available for Use in Cancer-Related Research

By BiotechDaily International staff writers
Posted on 08 Aug 2011
Cancer researchers now have access to 23 novel, cancer-related rabbit monoclonal antibodies that have been released to the commercial market.

The antibodies are the fruit of cooperation between the [US] National Cancer Institute (Bethesda, MD, USA) and the biotechnology company Epitomics, Inc. (Burlingame, CA, USA). Epitomics has developed a unique and proprietary method for making monoclonal antibodies from rabbits rather than the conventional method of starting with mice.

The basic principal for making the antibody is the same as for mouse monoclonal antibodies. Proprietary rabbit fusion-partner cells fuse to rabbit B-cells to create rabbit hybridoma cells. Hybridomas are then screened to select for clones with specific and sensitive antigen recognition, and the antibodies are characterized using a variety of methods. The rabbit immune system generates antibody diversity and optimizes affinity by mechanisms that are more efficient than those of mice and other rodents. This increases the possibility of obtaining a functional antibody that will work in a variety of applications.

This technology - combined with the expertise of researchers at the National Cancer Institute – has produced a line of 23 rabbit monoclonal antibodies that should be of use to cancer investigators. The antibodies are available for purchase in the United States directly through Epitomics and around the world through Epitomics’ international distributors. The collaborators plan to develop another 20 antibodies for commercial release over the next two years.

“We are very excited to see the progress we have made in developing several key antibodies with National Cancer Institute investigators and look forward to continuing working with them to develop high quality rabbit monoclonal antibodies,” said Dr. Guo-Liang Yu, CEO of Epitomics, Inc.

Related Links:

National Cancer Institute
Epitomics, Inc.



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.